Equities research analysts predict that Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Rating) will announce ($0.05) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Regulus Therapeutics’ earnings. Regulus Therapeutics reported earnings of ($0.08) per share in the same quarter last year, which suggests a positive year over year growth rate of 37.5%. The business is expected to report its next earnings results on Monday, January 1st.
On average, analysts expect that Regulus Therapeutics will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.19). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Regulus Therapeutics.
Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). During the same period last year, the business posted ($0.03) EPS.
Hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its position in shares of Regulus Therapeutics by 38.8% during the third quarter. Commonwealth Equity Services LLC now owns 111,000 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 31,000 shares during the last quarter. Morgan Stanley raised its holdings in Regulus Therapeutics by 2,799.7% during the 1st quarter. Morgan Stanley now owns 163,251 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 157,621 shares during the last quarter. Geode Capital Management LLC boosted its position in Regulus Therapeutics by 13.8% during the third quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 81,551 shares during the last quarter. Asymmetry Capital Management L.P. boosted its position in shares of Regulus Therapeutics by 94.9% during the 4th quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 1,329,553 shares in the last quarter. Finally, DAFNA Capital Management LLC acquired a new stake in Regulus Therapeutics during the fourth quarter worth approximately $1,750,000. 51.47% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ RGLS traded down $0.02 during midday trading on Monday, reaching $0.23. The company’s stock had a trading volume of 22,025 shares, compared to its average volume of 1,323,579. Regulus Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $1.55. The stock has a market capitalization of $33.57 million, a price-to-earnings ratio of -0.70 and a beta of 2.16. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $0.27 and a 200-day simple moving average of $0.35.
About Regulus Therapeutics (Get Rating)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.